The company, in a 2022 white paper, acknowledged that its vaccine, BNT162b2, may be causing myocarditis—which is heart inflammation—and a related condition called pericarditis. Pfizer scientists claimed that the inflammation likely wasn’t the result of direct cardiotoxicity but didn’t rule out several other possible mechanisms, including that it stemmed from immune activity."Although the BNT162b2 mRNA vaccine is optimized ... it is possible, especially in certain individuals with genetic predisposition and underlying conditions that the immune responses to mRNA may not be sufficiently turned down and drive the activation of an innate and adaptive immune response," the scientists wrote in the white paper. "This may lead to the excessive activation of proinflammatory cascades which contribute to the development of myocarditis," they wrote.
In the February 2022 paper, obtained and published by Project Veritas, Pfizer employees say that the company hadn’t defined myocarditis as an adverse reaction to its vaccine, meaning it hadn’t agreed that its vaccine causes myocarditis. It claimed
Including the Florida Surgeon General report
Cardiologist Dr. Peter McCullough reviewed the paper. He told The Epoch Times via email that the lipid nanoparticles in the mRNA shot are "widely distributed in the body in the circulation for a month or more," which "allows myocardial blood flow to repeatedly bathe the heart with vaccine products activating systemic and tissue immune response."
Dr. Robert Malone, who helped develop the mRNA technology, said that lipid nanoparticles do activate the human immune system and that the RNA in the vaccine leads to inflammatory responses in the cells and tissues.
"This strong proinflammatory response of the mRNA/lipoplexes is the reason I (and others including [biotechnology company] Genzyme) abandoned further research into this technology in the late 1990s and turned to other delivery methods such as direct (’naked’) injection and use of pulsed electrical fields," Malone told The Epoch Times via email.